TMEM89 Inhibitors
TMEM89 inhibitors encompass a diverse array of chemical compounds that suppress the functional activity of TMEM89 by targeting specific signaling pathways and cellular processes in which TMEM89 is involved. For instance, Rapamycin and Torin 1, both mTOR inhibitors, would lead to a decrease in TMEM89 activity by downregulating mTOR pathway signaling, a pathway known to control a range of cellular functions including cell growth and metabolism that TMEM89 may influence. Similarly, the MEK inhibitors PD 98059 and U0126 would reduce TMEM89 activity by blocking the phosphorylation and activation of ERK, which is part of the MAPK signaling cascade, potentially connected to TMEM89's function. PI3K/Akt pathway inhibitors such as LY 294002 and GSK2126458 effectively diminish TMEM89 activity by preventing activation within this critical signaling axis, which may modulate TMEM89. Bafilomycin A1, targeting V-ATPase, disrupts lysosomal function and autophagy, processes that could be fundamental to the regulation of TMEM89.
Further, compounds like WZB117 that inhibit GLUT1 reduce glycolytic activity, thereby potentially affecting TMEM89's role in cellular metabolism. SB 203580, a p38 MAP kinase inhibitor, could lead to diminished TMEM89 activity by modulating stress response pathways in which TMEM89 might play a part. Cycloheximide, by halting protein synthesis, indirectly reduces TMEM89 levels and activity. Additionally, Trichostatin A, through HDAC inhibition, could alter gene expression patterns and consequently TMEM89 activity if it is regulated by acetylation or HDAC-sensitive transcriptional mechanisms. Collectively, these TMEM89 inhibitors act through distinct but interrelated mechanisms, each leading to decreased activity of TMEM89 by influencing the specific pathways or cellular processes that govern its function.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR (mammalian target of rapamycin), which is a central protein in regulating cell growth and metabolism. TMEM89 is thought to be involved in processes that are regulated by the mTOR pathway. Inhibition of mTOR by rapamycin would lead to diminished TMEM89 activity as part of the downstream effects. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of MEK, which is upstream of the ERK pathway. As TMEM89 is implicated in signaling cascades that are regulated by the ERK pathway, inhibition by PD 98059 would lead to a decrease in the phosphorylation of ERK, thereby leading to a decrease in TMEM89 activity within this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of the PI3K/Akt pathway, a pivotal signaling route for numerous cellular functions. By inhibiting PI3K, LY 294002 would suppress Akt activation. Since TMEM89 is potentially modulated by the PI3K/Akt pathway, LY 294002 would indirectly diminish the functional activity of TMEM89 through this inhibition. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $49.00 $124.00 $441.00 $828.00 | 4 | |
WZB117 is a glucose transporter 1 (GLUT1) inhibitor. By inhibiting glucose uptake, WZB117 can lead to reduced glycolytic flux, thereby affecting energy metabolism. TMEM89, being associated with cellular metabolic processes, may have its activity diminished as a result of the metabolic stress and altered energy balance caused by WZB117. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a specific inhibitor of p38 MAP kinase. The p38 MAPK pathway is involved in stress responses, inflammation, and apoptosis. Inhibition of p38 by SB 203580 could lead to reduced functional activity of TMEM89 if TMEM89 is connected to signaling events regulated by p38 MAPK, thus indirectly reducing TMEM89 activity through pathway inhibition. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase (V-ATPase). By inhibiting V-ATPase, it disrupts lysosomal acidification and autophagy, which are crucial for cellular homeostasis. As TMEM89 is a transmembrane protein, its function could be diminished due to disruptions in autophagic processes and lysosomal function caused by Bafilomycin A1. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is an inhibitor of eukaryotic protein biosynthesis, acting by interfering with the translocation step in protein synthesis. As TMEM89 is a protein, its functional activity would be diminished due to the inhibition of its synthesis and the subsequent reduction in its cellular levels caused by cycloheximide. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, which prevents the activation of the downstream kinase ERK. If TMEM89 activity is regulated by the MEK/ERK pathway, U0126 could indirectly lead to diminished TMEM89 activity by preventing the activation of this signaling pathway. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
GSK2126458 is a dual inhibitor of PI3Kγ and mTOR. By simultaneously targeting both PI3K and mTOR, it effectively suppresses the PI3K/Akt/mTOR signaling axis. TMEM89, if it operates within this axis, would have decreased activity as GSK2126458 inhibits the pathway, thus indirectly leading to functional inhibition of TMEM89. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs). By modifying chromatin structure and affecting gene expression, it can influence various cellular pathways. If TMEM89 is regulated by acetylation states or by genes sensitive to HDAC activity, its activity could be diminished by the altered expression patterns caused by Trichostatin A. | ||||||